Safety and Efficacy of PD‐1/PD‐L1 inhibitors combined with radiotherapy in patients with non‐small‐cell lung cancer: a systematic review and meta‐analysis

BACKGROUND: A combination of programmed cell death protein‐1 (PD‐1)/programmed cell death ligand‐1 (PD‐L1) inhibitors and radiotherapy (RT) is increasingly being used to treat non‐small‐cell lung cancer (NSCLC). However, the safety and efficacy of this approach remains controversial. We performed a...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Med
Auteurs principaux: Geng, Yichao, Zhang, Qiuning, Feng, Shuangwu, Li, Chengcheng, Wang, Lina, Zhao, Xueshan, Yang, Zhen, Li, Zheng, Luo, Hongtao, Liu, Ruifeng, Lu, Bing, Wang, Xiaohu
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2021
Sujets:
Clinical Cancer Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7926021/
https://ncbi.nlm.nih.gov/pubmed/33465302
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3718
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires